Good morning :)
$
₹
Maze Therapeutics, Inc. Common Stock

Maze Therapeutics, Inc. Common Stock

MAZE

NASDAQ
Asset Logo

Maze Therapeutics, Inc. Common Stock

MAZE

NASDAQ
$22.370.64% (-0.14)
$
₹
$22.370.64% (-0.14)
High
—
—
Low
—
—
Returns
—
—
1D
1W
1M
1Y
5Y
Max
Loading...
1D
1W
1M
1Y
5Y
Max

Healthcare

Biotechnology

Small Cap

With a market cap of $1.3B the stock is ranked 2528

Key Metrics

Key Metrics

PE TTM
PE TTM

Close price divided by the earnings per share for the trailing twelve months

—
PB
PB

Close price divided by the book value per share at the end of the most recent quarter

2.76
EPS TTM
EPS TTM

Net profit earned per share over the trailing twelve months (sum of the last 4 quarters)

$-2.44
PEG Ratio
PEG Ratio

Price-to-Earnings (P/E) ratio divided by the forecasted annual earnings per share (EPS) growth rate over the next five years

—
Profit Margin
Profit Margin

Net profit divided by the total revenue for the most recent financial year

0%
Dividend Yield
Dividend Yield

Annual dividend per share for the trailing twelve months divided by the close price

—

Analyst Ratings & Forecast
Analyst Ratings & Forecast

Based on 4 analysts' reports

Buy
4 analysts
Hold
0 analyst
Sell
0 analyst

Analysts expect a +177.73% price upside over the next year

Current Price$22.37
Target Price$62.54

Company Profile

Maze Therapeutics, Inc., a clinical stage biopharmaceutical company, develops small molecule precision medicines for the treatment of kidney and metabolic diseases in the United States. Its lead programs include MZE829, an oral small molecule inhibitor of apolipoprotein L1, or APOL1, which is in phase II clinical trial for the treatment of patients with APOL1 kidney disease; and MZE782, an oral small molecule inhibitor that is in phase II ready clinical trial for the treatment of phenylketonuria and chronic kidney disease. The company also develops MZE001, an investigational oral small molecule inhibitor of muscle-specific glycogen synthase clinical program for the treatment of Pompe disease. It has a license agreement with Trace Neuroscience, Inc. to discovery research program targets UNC13A; the Shionogi & Co., Ltd to research, develop, manufacture, and commercialize MZE001; and Neurocrine Biosciences, Inc. to discover research program that targets ATXN2. The company was formerly known as Modulus Therapeutics, Inc. and changed its name to Maze Therapeutics, Inc. in September 2018. The company was incorporated in 2017 and is based in South San Francisco, California.
Maze Therapeutics, Inc., a clinical stage biopharmaceutical company, develops small molecule precision medicines for the treatment of kidney and metabolic diseases in the United States. Its lead programs include MZE829, an oral small molecule inhibitor of apolipoprotein L1, or APOL1, which is in phase II clinical trial for the treatment of patients with APOL1 kidney disease; and MZE782, an oral small molecule inhibitor that is in phase II ready clinical trial for the treatment of phenylketonuria and chronic kidney disease. The company also develops MZE001, an investigational oral small molecule inhibitor of muscle-specific glycogen synthase clinical program for the treatment of Pompe disease. It has a license agreement with Trace Neuroscience, Inc. to discovery research program targets UNC13A; the Shionogi & Co., Ltd to research, develop, manufacture, and commercialize MZE001; and Neurocrine Biosciences, Inc. to discover research program that targets ATXN2. The company was formerly known as Modulus Therapeutics, Inc. and changed its name to Maze Therapeutics, Inc. in September 2018. The company was incorporated in 2017 and is based in South San Francisco, California.

Peers

Peers

Eli Lilly and Company
LLY
Eli Lilly and Company
P/E Ratio
38.75
38.75
1Y Return
51.34%
51.34%
Buy Reco %
77.41
77.41
Johnson & Johnson
JNJ
Johnson & Johnson
P/E Ratio
31.35
31.35
1Y Return
56.14%
56.14%
Buy Reco %
45.83
45.83
Merck & Company Inc
MRK
Merck & Company Inc
P/E Ratio
117.49
117.49
1Y Return
80.14%
80.14%
Buy Reco %
57.69
57.69
Novartis AG ADR
NVS
Novartis AG ADR
P/E Ratio
21.17
21.17
1Y Return
14.78%
14.78%
Buy Reco %
15.38
15.38
AstraZeneca PLC
AZN
AstraZeneca PLC
P/E Ratio
24.86
24.86
1Y Return
8.31%
8.31%
Buy Reco %
90.00
90.00

Peers & Comparison

Peers & Comparison

Comparing 2 stocks from
HealthcareBiotechnology

Valuation

Returns

Forecast

StockPE TTMPE TTMPBPBPEG RatioPEG Ratio
Maze Therapeutics, Inc. Common Stock -2.76-
Eli Lilly and Company38.7530.331.13
Johnson & Johnson31.357.652.83

Price Comparison

Price Comparison

1 Month

1 Year

5 Years

Loading...

Financials

Financials

Income

Balance Sheet

Cash Flow

-30
-34.5
20
-24.2
-44.7
Q3 2025
Q4 2025
Q1 2026
Q2 2026
Revenue
Net Income
Financial YearQ1 2024Q2 2024Q3 2024Q4 2024Q1 2025Q2 2025Q3 2025Q4 2025Q1 2026Q2 2026
Total Revenue01652.500000200
Net Income-32.49139.05-24.75-29.57-32.78-33.67-30.08-34.56-24.20-44.72
Net Profit Margin-84.27%-990.08%------121.03%-
See CostsAll values in $ Million

Frequently asked questions

  1. Maze Therapeutics, Inc. Common Stock (MAZE) share price today is $22.37 as of September 22, 2026 at 12:48 AM IST. The stock touched a day high of $23.08 and a day low of $21.92.

  2. Maze Therapeutics, Inc. Common Stock stock trades on NASDAQ under the ticker symbol MAZE.

  3. Maze Therapeutics, Inc. Common Stock's market capitalization is $1.25B as of September 22, 2026 at 12:48 AM IST.

  4. Maze Therapeutics, Inc. Common Stock's price-to-earnings (P/E) ratio is N/A as of September 21, 2026.

  5. Maze Therapeutics, Inc. Common Stock's price-to-book (P/B) ratio is 2.76 as of September 21, 2026.

  6. Yes, You can buy Maze Therapeutics, Inc. Common Stock shares from India through Tickertape, via our partnership with ViewTrade IFSC under the IFSCA Global Access framework, subject to RBI’s Liberalised Remittance Scheme (LRS) limits.

  7. Indian investors can buy Maze Therapeutics, Inc. Common Stock shares in three steps: 1. Search Maze Therapeutics, Inc. Common Stock on the Tickertape app and tap Invest. 2. Complete your one-time digital KYC. 3. Fund your account and buy from as low as $1 via fractional shares.

  8. Since Maze Therapeutics, Inc. Common Stock trades in USD, an Indian investor's INR returns depend on both the stock's price movement and the USD-INR exchange rate. If the rupee depreciates against the dollar, INR returns are boosted beyond the stock's USD return; if the rupee appreciates, INR returns are reduced.

  9. Indian investors can start investing in Maze Therapeutics, Inc. Common Stock (MAZE) shares from as little as $1 through fractional ownership on Tickertape - for example, $10 buys approximately 0.4469 shares at the current price of $22.37.

Loading...